

Erratum to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study

Emilio Iannitto,^{1,2} Simone Ferrero,³ Côme Bommier,^{4,5} Daniela Drandi,³ Martina Ferrante,³ Krime Bouabdallah,⁶ Sylvain Carras,⁷ Guido Gini,⁸ Vincent Camus,⁹ Salvatrice Mancuso,¹⁰ Luigi Marcheselli,¹¹ Angela Ferrari,¹² Michele Merli,¹³ Benoit Tessoulin,¹⁴ Caterina Stelitano,¹⁵ Kheira Beldjord,⁴ Giovanni Roti,¹⁶ Fabrice Jardin,⁸ Barbara Castagnari,¹⁷ Francesca Palombi,¹⁸ Lucile Baseggio,¹⁹ Alexandra Traverse-Glehen,²⁰ Claudio Tripodo,² Anna Marina Liberati,²¹ Margherita Parolini,²² Sara Usai,²³ Caterina Patti,²⁴ Massimo Federico,²⁵ Maurizio Musso,¹ Marco Ladetto,²⁶ Emanuele Zucca²⁷ and Catherine Thieblemont^{4,5}

¹La Maddalena Department of Oncology, Onco-Hematology and Bone Marrow Transplantation Unit, Palermo, Italy; ²Tumor Immunology Unit Department of Health Sciences, University of Palermo School of Medicine, Istituto di Patologia Generale, Palermo, Italy; ³Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy; ⁴Université Paris Cité, Paris, France; ⁵AP-HP, Hôpital Saint-Louis, Hemato-oncologie, Paris, France; ⁶CHU de Bordeaux - Hôpital Haut Lévêque and Centre François Magendie, Service d'Hématologie Clinique et Thérapie Cellulaire, Pessac, France; ⁷University Grenoble Alpes, Institute For Advanced Biosciences, INSERM U1209, CNRS UMR 5309, University Hospital, Molecular Biology and Hematology Departments, Grenoble, France; ⁸Ematologia AOU delle Marche, Ancona, Italy; ⁹Department of Hematology, Centre Henri Becquerel, Rouen, France; ¹⁰Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), Hematology Unit, University of Palermo, Italy; ¹¹Fondazione Italiana Linfomi ETS, Modena, Italy; ¹²Azienda Unità Sanitaria Locale-IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; ¹³Hematology, Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi, Varese, Italy; ¹⁴Nantes University Hospital and CRC2 NA, Nantes, France; ¹⁵UO Ematologia AO Bianchi-Melacrino-Morelli, Reggio Calabria, Italy; ¹⁶Dipartimento di Medicina e Chirurgia, Università di Parma, AOU di Parma, Parma, Italy; ¹⁷Department of Hematology, Ravenna Hospital, Ravenna, Italy; ¹⁸Hematology Unit, IRCCS Regina Elena National Cancer Institute, Roma, Italy; ¹⁹Laboratoire d'Hématologie Biologique, Groupement Hospitalier Lyon-Sud/Hospices Civils de Lyon, Lyon, France; ²⁰Service d'Anatomie Pathologique, Groupement Hospitalier Lyon-Sud/Hospices Civils de Lyon, Lyon, France; ²¹Oncohematology Unit, University of Perugia, Azienda Ospedaliera S. Maria, Terni, Italy; ²²Ematologia, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"- IRST, Meldola, Italy; ²³Ospedale Oncologico A. Businco, Cagliari, Italy; ²⁴U.O.C. di Oncoematologia Ospedali Riuniti Villa Sofia - Cervello, Palermo, Italy; ²⁵CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy; ²⁶University of Eastern Piedmont, Amedeo Avogadro S.S. Antonio and Biagio and Cesaro Arrigo Hospital, Alessandria, Italy and ²⁷IOSI, Oncology Institute of Southern Switzerland and IOR, Institute of Oncology Research IELSG International Extranodal Lymphoma Study, Bellinzona, Switzerland

Correspondence: E. Iannitto
emilio.iannitto@gmail.com

Received: November 22, 2024.
Accepted: November 22, 2024.

<https://doi.org/10.3324/haematol.2024.287031>

©2025 Ferrata Storti Foundation

Published under a CC BY-NC license



In the article by Iannitto E *et al.*,¹ entitled “Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study”, an author affiliation was incomplete. The affiliation of the 22nd author should be stated as: Ematologia, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” - IRST, Meldola, Italy, and not Ematologia, Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” - IRST, Meldola, Italy.

References

1. Iannitto E, Ferrero S, Bommier C et al. Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of	early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study. Haematologica. 2024;109(7):2297-2302.
---	--